AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection and with plans to enter into the operation of a business-to-business (“B2B”) e-commerce food platform focused on the sale of Asian-sourced food products, is releasing information on the results of a major follow-up study. The study enrolled more than 18,000 individuals, who were tested using AnPac Bio’s Cancer Differentiation Analysis (“CDA”) method in what the company believes is one of the largest multiyear, multicancer follow-up studies in the world. Depending on the CDA test results, participants were classified into high-risk, medium-risk and low-risk groups, with individuals from all three groups being contacted regularly and their health status recorded. Test results show a strong correlation between CDA test score and cancer occurrence, with the higher the CDA value, the higher the cancer risk, indicating that CDA technology is effective in finding and predicting the occurrence of cancer. According to the announcement, the study “fully validated that CDA method is a multicancer detection method, which is capable of detecting multiple cancer types with statistical significance.” Based on the results of the study, AnPac Bio’s CDA method may become a cost-effective, multicancer screening method.

To view the full press release, visit https://ibn.fm/proQx

About AnPac Bio-Medical Science Co. Ltd.

AnPac Bio is a biotechnology company focused on early cancer screening and detection, with 155 issued patents as of June 30, 2022. With two certified clinical laboratories in China and one CLIA- and CAP-accredited clinical laboratory in the United States, AnPac Bio performs a suite of cancer-screening and detection tests, including Cancer Differentiation Analysis (“CDA”), biochemical, immunological and genomics tests. The company intends to enter the business-to-business e-commerce food business with the formation of its wholly owned subsidiary Fresh2 Technology Inc. and the acquisition of Fresh2 Ecommerce Inc. For more information about the company, visit www.AnPacBio.com.

NOTE TO INVESTORS: The latest news and updates relating to ANPC are available in the company’s newsroom at https://ibn.fm/ANPC

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com

InvestorWire is part of the InvestorBrandNetwork